Targeting malignant B cells as antigen-presenting cells: @entity6801 agonist induces systemic regression of XXXX .

@entity1 @entity706 @entity5 @entity6801 @entity1893
Evaluation of: Brody JD, Ai WZ, Czerwinski DK et al. In situ vaccination with a @entity6801 agonist induces systemic @entity706 regression: a Phase I/II study. J. Clin. Oncol. 28(28), 4324-4332 (2010). Despite high response rates of the follicular B-cell @entity706 to monoclonal antibodies, the clinical course of @entity706 is still characterized by a continuous pattern of relapse. Brody and colleagues treated 15 @entity1 with relapsed, @entity1893 using low-dose radiotherapy applied to one of the @entity5 sites with combined injection of a @entity6801 agonist at the same site. This strategy induced specific immunity and @entity5 regression in several @entity1 with an objective response rate of 27%. The results indicate an involvement of the @entity5 @entity6801 -expressing B cells acting as antigen-presenting cells. @entity6801 in situ vaccination combined with local radiotherapy clearly warrants further in-depth analysis and investigation in a Phase III randomized trial, and may provide a new opportunity for the treatment of B-cell @entity5 .
